• Research Interests

    Recent clinical trials have shown that T cell therapy, which makes use of the host's own immune system, can “cure” some cancer patients, such as CD19-specific chimeric antigen receptor (CAR) redirected T cell therapy for B-cell malignancies, adoptive transfer of tumor infiltrating lymphocytes (TILs) for melanoma, cholangiocarcinoma and cervical cancer. However, only a small population of patients now can benefit from this kind of immunotherapy. Our lab is interested in developing engineered tumor-specific T cells for treating more cancer patients.

    Current projects include:
    1:Targeting cancer stem cells (CSCs) by CAR T cells for the treatment of cancer patients.
    2:Combination of CRISPR/cas9 system and CAR technology for producing activated tumor-specific CAR T cells.